Literature DB >> 11825974

Comparison of three commercially available peptide-based immunoglobulin G (IgG) and IgA assays to microimmunofluorescence assay for detection of Chlamydia trachomatis antibodies.

Servaas A Morré1, Christian Munk, Kenneth Persson, Susanne Krüger-Kjaer, Rogier van Dijk, Chris J L M Meijer, Adriaan J C van Den Brule.   

Abstract

Three commercially available, peptide-based enzyme-linked immunosorbent assay (ELISA) systems (Chlamydia trachomatis IgG and IgA EIA [CT-EIA; Labsystems OY, Helsinki, Finland], SeroCT IgG and IgA [SeroCT; Savyon Diagnostics Ltd., Ashdod, Israel], and Chlamydia trachomatis IgG and IgA pELISA [CT pELISA; Medac, Wedel, Germany]) were evaluated for the detection of serum immunoglobulin G (IgG) and IgA antibodies specific for Chlamydia trachomatis and compared to the "gold standard" assay, the microimmunofluorescence (MIF) assay. Serological responses were analyzed in 149 women aged 20 to 30 years. Cervical swabs obtained from these women were examined for C. trachomatis by PCR, and 43 were found to be positive. The overall seroprevalence rates detected by CT-EIA, SeroCT, CT pELISA, and the MIF assay were 42, 42, 35, and 39%, respectively, for IgG and 7, 7, 3, and 7%, respectively, for IgA. The IgG seroprevalence rates for the PCR-positive women were two to three times higher than those for the PCR-negative women, i.e., 72 versus 29%, 72 versus 29%, 47 versus 26%, and 74 versus 25% for CT-EIA, SeroCT, CT pELISA, and the MIF assay, respectively. After discrepancy analysis, the sensitivity, specificity, positive predictive value, and negative predictive value were calculated for the IgG assays; for CT-EIA they were 84.7, 98.6, 98.4, and 86.7%, respectively; for CT pELISA they were 71.4, 97.3, 96.2, and 78.3%, respectively; for SeroCT they were 84.7, 98.6, 98.4, and 86.3%, respectively; and for the MIF assay they were 79.2, 83.1, 98.3, and 83.1%, respectively. In conclusion, these peptide-based ELISA systems for the serological detection of C. trachomatis infection performed as well as the MIF assay. Since these tests are less time-consuming, less expensive, and easier to perform than the MIF assay, they might be useful in the serodiagnosis of chlamydial infection.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11825974      PMCID: PMC153365          DOI: 10.1128/JCM.40.2.584-587.2002

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  8 in total

1.  Serotypes of Chlamydia trachomatis and risk for development of cervical squamous cell carcinoma.

Authors:  T Anttila; P Saikku; P Koskela; A Bloigu; J Dillner; I Ikäheimo; E Jellum; M Lehtinen; P Lenner; T Hakulinen; A Närvänen; E Pukkala; S Thoresen; L Youngman; J Paavonen
Journal:  JAMA       Date:  2001-01-03       Impact factor: 56.272

2.  Comparison of five serologic tests for diagnosis of acute infections by Chlamydia pneumoniae.

Authors:  K Persson; J Boman
Journal:  Clin Diagn Lab Immunol       Date:  2000-09

3.  RNA amplification by nucleic acid sequence-based amplification with an internal standard enables reliable detection of Chlamydia trachomatis in cervical scrapings and urine samples.

Authors:  S A Morré; P Sillekens; M V Jacobs; P van Aarle; S de Blok; B van Gemen; J M Walboomers; C J Meijer; A J van den Brule
Journal:  J Clin Microbiol       Date:  1996-12       Impact factor: 5.948

4.  A non-radioactive PCR enzyme-immunoassay enables a rapid identification of HPV 16 and 18 in cervical scrapes after GP5+/6+ PCR.

Authors:  M V Jacobs; A J van den Brule; P J Snijders; T J Helmerhorst; C J Meijer; J M Walboomers
Journal:  J Med Virol       Date:  1996-07       Impact factor: 2.327

5.  Chlamydia trachomatis species specific serology: ImmunoComb Chlamydia bivalent versus microimmunofluorescence (MIF).

Authors:  A Clad; H Freidank; J Plünnecke; B Jung; E E Petersen
Journal:  Infection       Date:  1994 May-Jun       Impact factor: 3.553

6.  Serological cross-reactions between Acinetobacter calcoaceticus and chlamydiae.

Authors:  H Brade; H Brunner
Journal:  J Clin Microbiol       Date:  1979-12       Impact factor: 5.948

7.  Human papillomavirus--the most significant risk determinant of cervical intraepithelial neoplasia.

Authors:  S K Kjaer; A J van den Brule; J E Bock; P A Poll; G Engholm; M E Sherman; J M Walboomers; C J Meijer
Journal:  Int J Cancer       Date:  1996-03-01       Impact factor: 7.396

8.  Enzyme immunoassay with enhanced specificity for detection of antibodies to Chlamydia trachomatis.

Authors:  J M Ossewaarde; A de Vries; J A van den Hoek; A M van Loon
Journal:  J Clin Microbiol       Date:  1994-06       Impact factor: 5.948

  8 in total
  27 in total

1.  [Diagnosis and treatment of Chlamydia trachomatis infections].

Authors:  T Meyer
Journal:  Hautarzt       Date:  2012-01       Impact factor: 0.751

2.  Comparison of five commercial serological tests for the detection of anti-Chlamydia trachomatis antibodies.

Authors:  D Baud; L Regan; G Greub
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-03-28       Impact factor: 3.267

Review 3.  [Modern diagnosis of Chlamydia trachomatis infections].

Authors:  T Meyer
Journal:  Hautarzt       Date:  2007-01       Impact factor: 0.751

4.  A novel synthetic peptide microarray assay detects Chlamydia species-specific antibodies in animal and human sera.

Authors:  Konrad Sachse; Kh Shamsur Rahman; Christiane Schnee; Elke Müller; Madlen Peisker; Thomas Schumacher; Evelyn Schubert; Anke Ruettger; Bernhard Kaltenboeck; Ralf Ehricht
Journal:  Sci Rep       Date:  2018-03-16       Impact factor: 4.379

5.  A serological study of the role of Mycoplasma genitalium in pelvic inflammatory disease and ectopic pregnancy.

Authors:  Margaretha Jurstrand; Jørgen Skov Jensen; Anders Magnuson; Francis Kamwendo; Hans Fredlund
Journal:  Sex Transm Infect       Date:  2007-05-02       Impact factor: 3.519

6.  Seroprevalences of herpes simplex virus type 2, five oncogenic human papillomaviruses, and Chlamydia trachomatis in Katowice, Poland.

Authors:  Staffan Görander; Teresa Lagergård; Malgorzata Romanik; Raphael P Viscidi; Gayane Martirosian; Jan-Ake Liljeqvist
Journal:  Clin Vaccine Immunol       Date:  2008-02-20

7.  Serodiagnosis of Echinococcus spp. infection: explorative selection of diagnostic antigens by peptide microarray.

Authors:  Claudia List; Weihong Qi; Eva Maag; Bruno Gottstein; Norbert Müller; Ingrid Felger
Journal:  PLoS Negl Trop Dis       Date:  2010-08-03

8.  Pgp3 antibody enzyme-linked immunosorbent assay, a sensitive and specific assay for seroepidemiological analysis of Chlamydia trachomatis infection.

Authors:  Gillian S Wills; Patrick J Horner; Rosy Reynolds; Anne M Johnson; David A Muir; David W Brown; Alan Winston; Andrew J Broadbent; David Parker; Myra O McClure
Journal:  Clin Vaccine Immunol       Date:  2009-04-08

9.  Immunoglobulin-specific responses to Chlamydia elementary bodies in individuals with and at risk for genital chlamydial infection.

Authors:  William M Geisler; Sandra G Morrison; Martha L Doemland; Shehzad M Iqbal; Jin Su; Ausra Mancevski; Edward W Hook; Richard P Morrison
Journal:  J Infect Dis       Date:  2012-10-08       Impact factor: 5.226

10.  Plasma antibodies against Chlamydia trachomatis, human papillomavirus, and human herpesvirus type 8 in relation to prostate cancer: a prospective study.

Authors:  Siobhan Sutcliffe; Edward Giovannucci; Charlotte A Gaydos; Raphael P Viscidi; Frank J Jenkins; Jonathan M Zenilman; Lisa P Jacobson; Angelo M De Marzo; Walter C Willett; Elizabeth A Platz
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2007-08       Impact factor: 4.254

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.